Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions

Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions

Blog Article

Background: nasopharyngeal carcinoma (NPC) is a complex read more disease entity that mainly predominates in endemic regions.Real-world data with immunotherapy from nonendemic regions are limited.Methods: we collected data from patients with recurrent/metastatic (R/M) NPC treated at a center in Greece and 8 centers in Italy.

Between 2016 and 2021, 46 patients who were treated with at least one cycle of immune checkpoint inhibitors (ICI) were identified.Herein, we present our results and a review of the literature.Results: assessment of response was available in 42 patients.

Overall, 11 patients responded to immunotherapy (Overall Response Rate-ORR 26.2%).Three patients had complete response (CR), and 8 patients had partial response (PR).

Disease control rate (DCR) was 61.9%.Median Progression Free Survival (PFS) was 5.

6 months and median Overall Survival (OS) was 19.1 months.Responders to ICI improved PFS and OS as compared to that of nonresponders.

A lower probability of responding to ICI was shown in patients with more than three metastatic sites (p = 0.073), metastatic disease at initial diagnosis, (p = 0.039) or EBV DNA positive before ICI initiation, (p = 0.

074).Decline in EBV DNA levels was found to be statistically significant associated with best response to ICI (p = 0.049).

Safety was manageable.Conclusions: among 46 patients with R/M NPC treated with immunotherapy in two nonendemic regions, ORR was 26.2% and durable responses were observed.

Low disease burden could serve as a biomarker for response jilungin dreaming tea to ICI.